Sucraid® Is an Effective Treatment for CSID
Three clinical trials have evaluated the therapeutic benefits of sacrosidase (the generic name for Sucraid®).
In This Section
The first study used the sucrose hydrogen breath test to measure the activity of sacrosidase in study participants diagnosed with Congenital Sucrase-Isomaltase Deficiency (CSID).
The therapeutic benefit of the replacement enzyme was measured by the hydrogen breath test, which measures the activity of the sucrase enzyme (see the breath tests). This study also measured the ability of four different doses of the replacement enzyme sacrosidase to relieve GI symptoms associated with CSID. The study included 14 patients, average age of 7.6 years, who were diagnosed with CSID. When they were given sacrosidase, results from the sucrose hydrogen breath test indicated a highly significant improvement in their ability to digest the sucrose. Among the four doses tested, the higher doses of sacrosidase resulted in greater relief of GI symptoms. The researchers concluded that sacrosidase is an effective and well-tolerated treatment for sucrase deficiency associated with CSID.1
In the second clinical trial, the researchers also used the hydrogen breath test to measure the activity of sacrosidase, taken by the study participants diagnosed with CSID.
The relief of GI symptoms was also measured after treatment with four different doses of sacrosidase. There were 28 study participants, average age 4 years, who were diagnosed with CSID. This study also used the sucrose hydrogen breath test, and found that sacrosidase significantly improved sucrose digestion. The frequency and severity of GI symptoms were greatly diminished with sacrosidase. 81% of the participants were free of GI symptoms during treatment with sacrosidase, defined as being symptom-free for at least 7 of the 10 treatment days. The researchers concluded that treatment with sacrosidase would allow consumption of a more normal diet in patients with CSID.2
The third clinical trial was conducted over a period of several years in 32 participants diagnosed with CSID and treated with Sucraid®.
The researchers again found therapy with Sucraid® to be well-tolerated and effective in reducing the GI symptoms of sucrase deficiency associated with CSID. Study participants in this long-term study spanned a broad range of ages. While taking Sucraid®, the study participants consumed a normal, sucrose-containing diet and experienced fewer GI symptoms than before therapy with Sucraid®.3
- Treem WR, Ahsan N, Sullivan B, et al. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency. Gastroenterology. 1993;105(4):1061-1068. doi:10.1016/0016-5085(93)90950-h
- Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for Congenital Sucrase-Isomaltase Deficiency. J Pediatr Gastroenterol Nutr. 1999;28(2):137-142. doi:10.1097/00005176-199902000-00008
- QOL Medical, LLC. Open-label, long-term study of sucrase enzyme therapy for Congenital Sucrase-Isomaltase Deficiency. Data on file, OMC-SUC-3. 1997.